Hostname: page-component-7479d7b7d-t6hkb Total loading time: 0 Render date: 2024-07-09T05:20:57.737Z Has data issue: false hasContentIssue false
  • English
  • Français

Selenium and cancer treatment

Published online by Cambridge University Press:  11 September 2013

Get access

In a nutshell

Selenium has potential use to help immunity and enhance recovery in cancer treatment, as an adjunct to sensitise tissues for other therapies, or to counter side-effects of those therapies.

The evidence base is currently stronger from animal and in vitro studies than human trials, although it includes some RCTs. Safe dose is an important issue.

Type
Brief Report
Information
Arbor Clinical Nutrition Updates , Volume 317 , February 2010 , pp. 1 - 5
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References:

1. Husbeck, B. et al. Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate. 2006 Feb 1;66(2):218–25.CrossRefGoogle ScholarPubMed
2. Thomson, CD. Assessment of requirements for selenium and adequacy of selenium status: a review. Eur J Clin Nutr. 2004 Mar;58(3):391–402.CrossRefGoogle ScholarPubMed
3. Micke, O. et al. Selenium in oncology: from chemistry to clinics. Molecules. 2009 Oct 12;14(10):3975–88.CrossRefGoogle ScholarPubMed
4. Maehira, F. et al. Alterations of serum selenium concentrations in the acute phase of pathological conditions. Clin Chim Acta. 2002 Feb;316(1–2):137–46.CrossRefGoogle ScholarPubMed
5. Sattar, N. et al. Acute-phase reactants and plasma trace element concentrations in non-small cell lung cancer patients and controls. Nutr Cancer. 1997;28(3):308–12.Google Scholar
6. Mayland, C. et al. Micronutrient concentrations in patients with malignant disease: effect of the inflammatory response. Ann Clin Biochem. 2004 Mar;41(Pt 2):138–41.CrossRefGoogle ScholarPubMed
7. Beuth, J. et al. Selenium in oncology. p.171–182 in: Complementary oncology: adjunctive methods in the treatment of cancer. Georg Thema Verlag, Stuttgart, 2006.Google Scholar
8. Charalabopoulos, K. et al. Serum and tissue selenium levels in gastric cancer patients and correlation with CEA. Anticancer Res. 2009 Aug;29(8):3465–7.Google ScholarPubMed
9. Asfour, IA. et al. Selenium and Glutathione Peroxidase Status in Adult Egyptian Patients with Acute Myeloid Leukemia. Biol Trace Elem Res. 2009 May 21.Google Scholar
10. Last, KW. et al. Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2003 Jun 15;21(12):2335–41.CrossRefGoogle ScholarPubMed
11. Büntzel, J. et al. Serum selenium in head and neck cancer patients--a new marker of tumor activity? Anticancer Res. 2005 May-Jun;25(3A):1711–2.Google Scholar
12. Yu, B. et al. [The relationship between selenium and immunity in large bowel cancer] Zhonghua Wai Ke Za Zhi. 1996 Jan;34(1):50–3.Google ScholarPubMed
13. Faber, M. et al. Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin. A preliminary study. Biol Trace Elem Res. 1995 Jan-Mar;47(1–3):117–23.CrossRefGoogle ScholarPubMed
14. Vernie, LN. et al. Cisplatin-induced changes of selenium levels and glutathione peroxidase activities in blood of testis tumor patients. Cancer Lett. 1988 May;40(1):83–91.CrossRefGoogle ScholarPubMed
15. Anon. Selen in der Krebsmedizin Wissenschaftliche Gesellschaft zur Förderung der Patientenkompetenz. 2005.Google Scholar
16. Last, K. et al. The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours. Ann Oncol. 2006 May;17(5):773–9.CrossRefGoogle ScholarPubMed
17. Hiraoka, K. et al. Osteosarcoma cell apoptosis induced by selenium. J Orthop Res. 2001 Sep;19(5):809–14.Google Scholar
18. Sinha, R. et al. Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr Cancer Drug Targets. 2004 Feb;4(1):13–28.CrossRefGoogle ScholarPubMed
19. Lockwood, K. et al. Apparent partial remission of breast cancer in ‘high risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med. 1994;15 Suppl:s231–40.Google Scholar
20. Lawenda, BD. et al. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst. 2008 Jun 4;100(11):773–83.CrossRefGoogle ScholarPubMed
21. Bhutani, M. et al. Re: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst. 2008 Sep 17;100(18):1334.CrossRefGoogle ScholarPubMed
22. Block, K. et al. Re: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst. 2009 Jan 21;101(2):124–5.Google Scholar
23. Simone, CB. et al. Re: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst. 2008 Nov 5;100(21):1558–9.CrossRefGoogle ScholarPubMed
24. Simone, CB 2nd. et al. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, Part 2. Altern Ther Health Med. 2007 Mar-Apr;13(2):40–7.Google ScholarPubMed
25. Simone, CB 2nd. et al. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med. 2007 Jan-Feb;13(1):22–8.Google Scholar
26. Prasad, KN. et al. Pros and cons of antioxidant use during radiation therapy. Cancer Treat Rev. 2002 Apr;28(2):79–91.CrossRefGoogle ScholarPubMed
27. Vadgama, JV. et al. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anticancer Res. 2000 May-Jun;20(3A):1391–414.Google Scholar
28. Schroeder, CP. et al. Effect of selenite combined with chemotherapeutic agents on the proliferation of human carcinoma cell lines. Biol Trace Elem Res. 2004 Summer;99(1–3):17–25.Google Scholar
29. Olas, B. et al. [Selenium in the cytotoxicity of cisplatin] Postepy Hig Med Dosw. 1997;51(1):95–108.Google ScholarPubMed
30. Dörr, W. Effects of selenium on radiation responses of tumor cells and tissue. Strahlenther Onkol. 2006 Dec;182(12):693–5.Google Scholar
31. Jüliger, S. et al. Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-kappaB inhibition and the rapid generation of other selenium species. Cancer Res. 2007 Nov 15;67(22):10984–92.Google Scholar
32. Yamaguchi, K. et al. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene. 2005 Sep 1;24(38):5868–77.Google Scholar
33. Altundag, K. et al. Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients. Med Hypotheses. 2005;64(6):1162–5.Google Scholar
34. Harris, AL. et al. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol. 1992;31(2):205–13.CrossRefGoogle ScholarPubMed
35. Caffrey, PB. et al. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo. Cancer Chemother Pharmacol. 2000;46(1):74–8.Google Scholar
36. Jönsson-Videsäter, K. et al. Selenite-induced apoptosis in doxorubicin-resistant cells and effects on the thioredoxin system. Biochem Pharmacol. 2004 Feb 1;67(3):513–22.CrossRefGoogle ScholarPubMed
37. Dennert, G. et al. Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. Cochrane Database Syst Rev. 2006 Jul 19;3:CD005037.Google Scholar
38. Sieja, K. et al. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol. 2004 May;93(2):320–7.CrossRefGoogle ScholarPubMed
39. Wachowicz, B. et al. Comparative cytotoxicity of cisplatin, sodium selenite and selenium-cisplatin conjugate [(NH3)2Pt(SeO3)]; changes of blood platelet activation. Gen Physiol Biophys. 1997 Sep;16(3):263–72.Google ScholarPubMed
40. Francescato, HD. et al. Effect of oral selenium administration on cisplatin-induced nephrotoxicity in rats. Pharmacol Res. 2001 Jan;43(1):77–82.Google Scholar
41. Vermeulen, NP. et al. Reduction of cisplatin nephrotoxicity by sodium selenite. Lack of interaction at the pharmacokinetic level of both compounds. Drug Metab Dispos. 1993 Jan-Feb;21(1):30–6.Google ScholarPubMed
42. Naziroglu, M. et al. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology. 2004 Feb 15;195(2–3):221–30.CrossRefGoogle ScholarPubMed
43. Baldew, GS. et al. The mechanism of interaction between cisplatin and selenite. Biochem Pharmacol. 1991 May 15;41(10):1429–37.Google Scholar
44. Hu, YJ. et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res. 1997 Mar;56(3):331–41.CrossRefGoogle ScholarPubMed
45. Sundström, H. et al. Supplementation with selenium, vitamin E and their combination in gynaecological cancer during cytotoxic chemotherapy. Carcinogenesis. 1989 Feb;10(2):273–8.CrossRefGoogle ScholarPubMed
46. Fakih, MG. et al. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors. Clin Cancer Res. 2006 Feb 15;12(4):1237–44.CrossRefGoogle ScholarPubMed
47. Saltiel, E. et al. Doxorubicin (adriamycin) cardiomyopathy. West J Med. 1983 Sep;139(3):332–41.Google Scholar
48. Sieber, F. et al. High-dose selenium for the mitigation of radiation injury: a pilot study in a rat model. Radiat Res. 2009 Mar;171(3):368–73.Google Scholar
49. Weiss, JF. et al. Radioprotection by metals: selenium. Adv Space Res. 1992;12(2–3):223–31.Google Scholar
50. Weiss, JF. et al. Selenium pretreatment enhances the radioprotective effect and reduces the lethal toxicity of WR-2721. Free Radic Res Commun. 1987;3(1–5):33–8.CrossRefGoogle ScholarPubMed
51. Weiss, JF. et al. Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology. 2003 Jul 15;189(1–2):1–20.CrossRefGoogle ScholarPubMed
52. Margulies, BS. et al. The differential effects of the radioprotectant drugs amifostine and sodium selenite treatment in combination with radiation therapy on constituent bone cells, Ewing's sarcoma of bone tumor cells, and rhabdomyosarcoma tumor cells in vitro. J Orthop Res. 2008 Nov;26(11):1512–9.Google Scholar
53. Gehrisch, A. et al. Effects of systemic or topical administration of sodium selenite on early radiation effects in mouse oral mucosa. Strahlenther Onkol. 2007 Jan;183(1):36–42.Google Scholar
54. Fraunholz, I. et al. Influence of selenium on acute mucositis in radiochemotherapy of head and neck tumors. Trace Elem. Electrolytes 2001;18:98–9.Google Scholar
55. Hehr, T. et al. [Role of sodium selenite as an adjuvant in radiotherapy of rectal carcinoma] Med Klin (Munich). 1997 Sep 15;92 Suppl 3:48–9.Google Scholar
56. Hammerl, B. et al. [Secondary malignant lymphedema in head and neck tumors] Wien Med Wochenschr. 2008;158(23–24):695–701.Google Scholar
57. Kasseroller, R. [Administration of selenium in lymphedema] Med Klin (Munich). 1997 Sep 15;92 Suppl 3:50–1.Google Scholar
58. Micke, O. et al. Selenium in the treatment of radiation-associated secondary lymphedema. Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):40–9.Google Scholar
59. Bruns, F. et al. Selenium in the treatment of head and neck lymphedema. Med Princ Pract. 2004 Jul-Aug;13(4):185–90.Google Scholar
60. Zimmermann, T. et al. Reduction of postoperative lymphedema after oral tumor surgery with sodium selenite. Biol Trace Elem Res. 2005 Sep;106(3):193–203.Google Scholar
61. Kasseroller, R. Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Res. 1998 May-Jun;18(3C):2227–30.Google ScholarPubMed
62. Kasseroller, RG. et al. Treatment of secondary lymphedema of the arm with physical decongestive therapy and sodium selenite: a review. Am J Ther. 2000 Aug;7(4):273–9.Google Scholar
63. Kiremidjian-Schumacher, L. et al. Selenium and immunocompetence in patients with head and neck cancer. Biol Trace Elem Res. 2000 Feb;73(2):97–111.CrossRefGoogle ScholarPubMed
64. Xu, B. et al. Randomized double-blind placebo-controlled phase II clinical trial of kappa-selenocarrageenan in cancer chemotherapy patients. Chinese Journal of Clinical Oncology 1999;26(9):678–80.Google Scholar
65. Lasch, K. et al. [Selenium therapy in colorectal tumors?] Med Klin (Munich). 1999 Oct 15;94 Suppl 3:97–100.Google Scholar
66. Pakdaman, A. Symptomatic treatment of brain tumor patients with sodium selenite, oxygen, and other supportive measures. Biol Trace Elem Res. 1998 Apr-May;62(1–2):1–6.Google Scholar
67. Holzhauer, P. Kann durch die prophylaktische Gabe von Natriumselenit die Inzidenz und der Schweregrad der durch Vinorelbin induzierten lokalen Phlebitis beeinflusst werden? Wissenschaft & Forschung 2002;34(1):14–16.Google Scholar
68. Spallholz, JE. On the nature of selenium toxicity and carcinostatic activity. Free Radic Biol Med. 1994 Jul;17(1):45–64.Google Scholar
69. Spallholz, JE. Free radical generation by selenium compounds and their prooxidant toxicity. Biomed Environ Sci. 1997 Sep;10(2–3):260–70.Google Scholar
70. Olson, OE. Selenium toxicity in animals with emphasis on man. J Am Coll Toxicol 1986;5:45–69.Google Scholar
71. Whanger, PD. Selenium and its relationship to cancer: an update. Br J Nutr. 2004 Jan;91(1):11–28.Google Scholar
72. Macfarquhar, JK. et al. Acute selenium toxicity associated with a dietary supplement. Arch Intern Med. 2010 Feb 8;170(3):256–61.Google Scholar
73. See, KA. et al. Accidental death from acute selenium poisoning. Med J Aust. 2006 Oct 2;185(7):388–9.CrossRefGoogle ScholarPubMed
74. Sakurai, H. et al. A tentative recommendation for the maximum daily intake of selenium. Environ Physiol Biochem. 1975;5(2):107–18.Google Scholar